{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:47:17Z","timestamp":1785829637391,"version":"3.56.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the rationale for using lemborexant 10\u00a0mg as a starting dose or for those with partial response to 5\u00a0mg for the management of insomnia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A review of MEDLINE, regulatory reports, and Canadian Agency for Drugs and Technologies in Health data was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Lemborexant 10\u00a0mg as an initial dose offers minimal improvement in sleep metrics over 5\u00a0mg but increases somnolence risk. No evidence supports dose escalation for partial responders to 5\u00a0mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lemborexant 10\u00a0mg is generally not advisable as an initial or escalated dose due to higher harm risk and unlikely clinical benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijpp\/riaf077","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:49:25Z","timestamp":1755085765000},"page":"502-504","source":"Crossref","is-referenced-by-count":0,"title":["Is bigger better? Analysis of efficacy and safety of lemborexant 5 versus 10\u00a0mg in insomnia patients"],"prefix":"10.1093","volume":"34","author":[{"given":"Eugene","family":"Chang","sequence":"first","affiliation":[{"name":"Vancouver Coastal Health Pharmacy Services , Vancouver General Hospital, 855 West 12th Avenue, Vancouver, BC V5Z 1M9 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5496-1470","authenticated-orcid":false,"given":"Aaron M","family":"Tejani","sequence":"additional","affiliation":[{"name":"Therapeutics Initiative, University of British Columbia , 2176 Health Sciences Mall, Vancouver, BC V6T 1Z3 ,","place":["Canada"]},{"name":"Fraser Health Pharmacy Services , 8521 198A Street, Langley, BC V2Y 0A1 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"2026080403074269700_ref1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.sleep.2021.03.028","article-title":"International study of the prevalence and factors associated with insomnia in the general population","volume":"82","author":"Aernout","year":"2021","journal-title":"Sleep Med"},{"key":"2026080403074269700_ref2","doi-asserted-by":"publisher","DOI":"10.1093\/sleepadvances\/zpab011","article-title":"Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study","volume":"2","author":"Mayleben","year":"2021","journal-title":"SLEEP Adv"},{"key":"2026080403074269700_ref3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5664\/jcsm.8294","article-title":"Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening","volume":"16","author":"Murphy","year":"2020","journal-title":"J Clin Sleep Med"},{"key":"2026080403074269700_ref4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.5664\/jcsm.6800","article-title":"Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study","volume":"13","author":"Murphy","year":"2017","journal-title":"J Clin Sleep Med"},{"key":"2026080403074269700_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"K\u00e4rpp\u00e4","year":"2020","journal-title":"Sleep"},{"key":"2026080403074269700_ref6","doi-asserted-by":"publisher","first-page":"e1918254","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of Lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial","volume":"2","author":"Rosenberg","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026080403074269700_ref7","volume-title":"DAYVIGO MONOGRAPH.Pdf [Internet]","year":"2020"},{"key":"2026080403074269700_ref8","volume-title":"Lemborexant (Dayvigo) [Internet]","year":"2023"},{"key":"2026080403074269700_ref9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of sleep medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J Clin Sleep MedJ Clin Sleep Med"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/34\/4\/502\/64418294\/riaf077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/34\/4\/502\/64418294\/riaf077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:07:46Z","timestamp":1785827266000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/article\/34\/4\/502\/8266843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":9,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9,27]]},"published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riaf077","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"value":"0961-7671","type":"print"},{"value":"2042-7174","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2025,9,27]]}}}